Management of castrate resistant prostate cancer - Recent advances and optimal sequence of treatments

Current Urology Reports

Volumn 14, Issue 3, 2013, Pages 174-183

  Zhang, Tian Yi ^a   Agarwal, Neeraj ^a   Sonpavde, Guru ^b   Dilorenzo, Giuseppe ^c   Bellmunt, Joaquim ^d   Vogelzang, Nicholas J ^e  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d HOSPITAL DEL MAR   (Spain)

^e Division of Hematology and Medical Oncology   (United States)

Author keywords

Abiraterone; Agents in phase 3 trials; Alpharadin (Radium 223); Androgen axis inhibitors; Cabazitaxel; Enzalutamide; Metastatic castration resistant prostate cancer; Optimal sequencing of novel agents; Sipuleucel T

Indexed keywords

ABIRATERONE ACETATE; AFLIBERCEPT; BEVACIZUMAB; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; DASATINIB; DOCETAXEL; ENZALUTAMIDE; IPILIMUMAB; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; SUNITINIB; TASQUINIMOD;

ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FATIGUE; FLUID RETENTION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY FAILURE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANDROSTENOLS; ANILIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; IMIDAZOLES; MALE; NAPHTHALENES; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRIDINES; QUINOLINES; RADIOISOTOPES; RADIUM; TAXOIDS; THIONUCLEOTIDES; TISSUE EXTRACTS;

EID: 84878731259     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0322-0     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419-24.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
4. Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
5. • Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2012;30:644-6. An excellent review of role of androgen signaling in the progression of castration resistant prostate cancer.
6. •• Drake JM, Graham NA, Stoyanova T, et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A. 2012;109:1643-8. Report from animal models showing elevated tyrosine kinase signaling in advanced prostate cancer, thus suggesting possibility of molecular stratification of patients to target prostate cancer with tyrosine kinase inhibitors even in tumors without obvious tyrosine kinase mutations.
7. •• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74. Landmark review on molecular biology underlying oncogenesis.
8. •• Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239-43. Report on novel molecular pathways driving progression of castrate resistance prostate cancer.
9. • Welty CJ, Coleman I, Coleman R, et al. Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol. 2013;14:6. Report on how transcriptomic profile can be reliably obtained from a single prostate cancer cell from the bone marrow of men with advanced prostate cancer, using commercially available technology.
10. • Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol. 2010;7:494-509. An excellent review on therapeutic targeting of prostate cancer micro environment.
11. • Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol. 2012;61:950-60. An excellent review of emerging therapeutic agents in castration resistant prostate cancer.
12. • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22. Original report of the Phase 3 trial leading to approval of sipuleucel-T in the treatment of metastatic CRPC.
13. Gomella LG, Nabhan C, DeVriesT et al. Estimating the overall survival benefit of sipuleucel-T in the IMPACT trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cryopreserved cells. AUA 2012. Abstract #683. 2012.
14. Chodak G, Schellhammer PF, Whitmore JB et al. Overall survival (OS) benefit with sipuleucel-T by baseline PSA: An exploratory analysis from the phase III IMPACT trial. J Clin Oncol 2012; 30: (suppl; abstr 4648)
15. Small EJ HC, Kantoff PW, et al. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. J Clin Oncol 29: 2011 (suppl; abstr 4661).
16. Small E J, Lance R, Gardner TA et al. A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 2013; 31: (suppl 6; abstr 114).
17. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
18. • de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-54. Original report of the Phase 3 trial leading to approval of cabazitaxel in the treatment of metastatic CRPC.
19. • de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005. Original report of the Phase 3 trial leading to approval of abiraterone acetate in the treatment of metastatic CRPC with prior chemotherapy.
20. • Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983-92. Updated report of the Phase 3 trial leading to approval of abiraterone acetate in the treatment of metastatic CRPC.
21. • Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-48. Original report of the Phase 3 trial leading to approval of abiraterone acetate in the treatment of metastatic CRPC without prior chemotherapy.
22. Goodman OB, Flaig TW, Molina A et al. Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2013; 31: (suppl 6; abstr 14).
23. • Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787-90. Original report of clinical development of diarylthiohydantoins RD162 and MDV3100 (enzalutamide) in CRPC.
24. • Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-97. Original report of the Phase 3 trial leading to approval of enzalutamide in the treatment of metastatic CRPC with prior chemotherapy.
25. Fleming MT, Scher HI, Fizazi K et al. Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. J Clin Oncol 2013; 31: (suppl 6; abstr 20).
26. • Bellmunt J. Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients. Eur Urol. 2013;63:198-200. Excellent review of radium-223 in the treatment of metastatic CRPC.
27. Sartor AO, Heinrich D, Helle SI et al. Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA). J Clin Oncol 2012; 30: (suppl 5; abstr 9).
28. Agus DA, Stadler WM, Shevrin DH et al. Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. J Clin Oncol 2012; 30: abstr 98.
29. Hussain M, Corn P, Michaelson D et al. Activity and Safety of the Investigational Agent Orteronel in Men With Nonmetastatic Castration-resistant Prostate Cancer and Rising Prostate-specific Antigen: Results of a Phase 2 Study. 27th Annual European Association of Urology, Paris, France, 2012; February 24-28: Poster 124.
30. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther. 2007;7:1245-56.
31. O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res. 2007;13:958-64.
32. • Vergati M, Intrivici C, Huen NY et al. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; 2010. Review of strategies employed by recent clinical trials of therapeutic cancer vaccines.
33. • Agarwal N, Padmanabh S, Vogelzang NJ. Development of novel immune interventions for prostate cancer. Clin Genitourin Cancer. 2012;10:84-92. An excellent review of immuno-modulatory agents in the treatment of advanced prostate cancer.
34. • Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580-93. A landmark review of the role of immunotherapy in the treatment of prostate cancer.
35. Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches. Semin Oncol. 2005;32:549-55.
36. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-105.
37. •• Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin Investig Drugs. 2010;19:1235-43. A landmark review of the discovery and development of tasquinimod for the treatment of prostate cancer.
38. • Isaacs JT, Antony L, Dalrymple SL, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment. Cancer Res. 2013;73:1386-99. Original report of identification of histone deacetylase HDAC4 as a target for the antiangiogenic activity of tasquinimod.
39. Kallberg E, Vogl T, Liberg D, et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS One. 2012;7:e34207.
40. • Pili R, Haggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022-8. Original report of the Phase 2 trial of tasquinimod in the treatment of metastatic CRPC.
41. • Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res. 2010;16:1088-93. An excellent review on the role of clusterin, inhibitor of cytoprotective chaperone, in the treatment of advanced cancer.
42. • Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:4247-54. Original report of the Phase 2 trial evaluating the role of OGX-011, inhibitor of cytoprotective chaperone, in the treatment of metastatic CRPC.
43. • Tu WH, Zhu C, Clark C, et al. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 2010;10:556. Pre-clinical report that c-Met inhibitors demonstrate anti-proliferative efficacy when combined with androgen ablation therapy for advanced prostate cancer.
44. • Smith DC, Smith MR, Sweeney C et al. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol 2012. Original report of the Phase 2 trial of cabozantinib in the treatment of metastatic CRPC.
45. • Attard G, Reid AH, de Bono JS. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol. 2010;28:e560-1. author reply e562. Report providing rationale and evidence that abiraterone acetate can be used with out concomitant corticosteroids.
46. •• Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17:5913-25. Report on how prostate cancer cells can acquire resistance to abiraterone acetate.